Effect of vitamin D on urinary angiotensinogen level in early diabetic nephropathy

Mahapatra, Himansu Sekhar; Kumar, Adarsh; Kulshreshtha, Bindu; Chitkara, Anubhuti; Kumari, Anamika

doi:10.4103/ijn.ijn_67_20

Cited by 7 publications

(13 citation statements)

References 25 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 The extraosseous advantage of vitamin D supplementation in preventing the development of early diabetic nephropathy was demonstrated in the research by Mahapatra. 14 However, whether vitamin D is involved in the occurrence and development of DFU remains controversial. Razzaghi et al 15 demonstrated that vitamin D supplementation for 12 weeks resulted in a significant improvement in DFU wound evolution, including ulcer length, width, depth, and erythema rate.…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Analysis of the Relationship Between 25-OH-Vitamin D and Diabetic Foot Ulcer

Wang¹,

Zhou²,

Zhu³

et al. 2022

DMSO

View full text Add to dashboard Cite

Background The fat-soluble molecule vitamin D has attracted much attention since its pleiotropism was discovered. Its effectiveness can be attributed to the presence of vitamin D receptors in most of the body’s tissues. Based on the classical role of vitamin D in regulating calcium and phosphorus metabolism and maintaining bone health, the role of vitamin D in immunity, type 2 diabetes mellitus (T2DM), tumor and cardiovascular diseases has been further discovered. Some experiments have shown that vitamin D can restore the production of antimicrobial peptides (AMP) in primary diabetic foot ulcer (DFU) cells, which can improve in vitro wound healing, indicating its potential therapeutic use in DFU therapy. In addition, vitamin D can also inhibit the secretion of T-helper type 1 (Th1) cytokines IFN-Y and IL-2 while stimulating the production of Th2 cytokines, thereby promoting wound healing. Objective To investigate the relationship between 25-OH-vitamin D level and DFU in diabetes mellitus (DM) patients, and to provide a theoretical basis for the early prevention and treatment of DFU. Methods The clinical data of 429 hospitalized patients with DM were retrospectively analyzed in this case–control study. The patients were divided into the DFU group (n = 242) and non-DFU group (n = 187). Fasting venous blood was drawn from all subjects to detect serum 25-OH-vitamin D levels and blood biochemical parameters, the difference of parameters between DFU group and non-DFU group were analyzed, and the risk factors of DFU were analyzed by logistic regression. Results The difference between the two groups in age, DM duration, gender, diastolic blood pressure, serum creatinine, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, albumin, white blood cell count, hemoglobin, hematocrit, 25-OH-vitamin D was statistically significant (p < 0.05). Multivariate logistic regression analysis showed that 25-OH-vitamin D is an independent protective factor for DFU [OR 95%, CI 0.984 (0.969, 0.998), p < 0.05]. 25-OH-vitamin D nutrition status distribution was different between non-DFU group and DFU group (P < 0.05). Vitamin D deficiency (< 50 nmol/L) accounted for 86.78% of all DFU patients, which was only 74.33% in non-DFU patients. The 25-OH-vitamin D levels of DFU patients from Wagner Grades 1 to 5 showed a downward trend (p < 0.01). Conclusion In conclusion, our study confirms that 25-OH-vitamin D is closely correlated with DFU and that 25-OH-vitamin D is an independent protective factor for DFU. Therefore, vitamin D screening or supplementation might be beneficial to prevent DFU and improve the prognosis of DM patients.

show abstract

Section: Introductionmentioning

confidence: 99%

A Retrospective Analysis of the Relationship Between 25-OH-Vitamin D and Diabetic Foot Ulcer

Wang¹,

Zhou²,

Zhu³

et al. 2022

DMSO

View full text Add to dashboard Cite

show abstract

“…VD3 has implicated in bone metabolism, but recently it has been identified as a potential contributor to the extraosseous pathophysiological conditions in many tissues and organs, including brain [17,24,25], kidney [26], immune system [27], skin [28], and others. Our previous results showed accelerated wound repair with VD3 but without complete repair [8].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Vitamin D3 and Silver Nanoparticles on HaCaT Cell Viability

Cataldi

Ceccarini

Patria

et al. 2022

IJMS

View full text Add to dashboard Cite

Vitamin D3, known to regulate bone homeostasis, has recently been shown to have many pleiotropic effects in different tissues and organs due to the presence of its receptor in a wide range of cells. Our previous study demonstrated that vitamin D3 was able to increase the wound healing respect to the control sample, 24 h after cutting, without however leading to a complete repair. The aim of the study was to combine vitamin D3 with silver nanoparticles to possibly enable a faster reparative effect. The results showed that this association was capable of inducing a complete wound healing only after 18 h. Moreover, a treatment of vitamin D3 + silver nanoparticles yielded a small percentage of keratinocytes vimentin-positive, suggesting the possibility that the treatment was responsible for epithelial to mesenchymal transition of the cells, facilitating wound healing repair. Since vitamin D3 acts via sphingolipid metabolism, we studied the expression of gene encoding for the metabolic enzymes and protein level. We found an increase in neutral sphingomyelinase without involvement of neutral ceramidase or sphingosine kinase2. In support, an increase in ceramide level was identified by Ultrafast Liquid Chromatography–Tandem Mass Spectrometry, suggesting a possible involvement of ceramides in wound healing process.

show abstract

“…In 3 of these, the control group experienced either a reduction or a nonsignificant change in 25(OH)D from baseline. 21,26,31 In the trial reported by Momeni et al, the control participants also had higher 25(OH)D levels at study end but the increase in the vitamin D-treated group was greater. 34 In the trial by Barzegari et al 29 and Esfandari et al, 30 25(OH)D levels increased in both groups.…”

Section: (Oh)d and Calcium Levelsmentioning

confidence: 95%

“…The decrease in triglycerides from baseline in the vitamin D group approached significance (P = .06), whereas levels remained stable in the placebo group (P = .62). Mahapatra et al 26 reported no significant between-group difference in triglyceride levels at baseline or study end. Barzegari et al 29 and Esfandiari et al 30 reported a decreased fasting blood sugar (FBS) and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) in the vitamin D group at study end, as well as a reduction in insulin levels that approached significance (P = .07).…”

Section: Vitamin D Supplementation and Proteinuriamentioning

confidence: 96%

“…Three of the 5 trials [28][29][30][31][32]35 reported no adverse effects throughout the study period. In 1 trial, 26 2 participants in the placebo group and 3 in the intervention group experienced self-limiting nausea which did not require discontinuation. There were no major adverse events in either group.…”

Section: Vitamin D Supplementation and Reporting Of Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Are There Any Pleiotropic Benefits of Vitamin D in Patients With Diabetic Kidney Disease? A Systematic Review of Randomized Controlled Trials

Sharma,

Khan,

Wilson

et al. 2023

Can J Kidney Health Dis

View full text Add to dashboard Cite

Background: Type 2 diabetes (T2D) and kidney disease are risk factors for vitamin D deficiency. Native forms of vitamin D have a lower risk of hypercalcemia than calcitriol, the active hormone. The enzyme responsible for activating native vitamin D is now known to be expressed throughout the body; therefore, native vitamin D may have clinically relevant effects in many body systems. Objective: The objective of this systematic review was to examine the effect of native vitamin D supplementation on clinical outcomes and surrogate laboratory measures in patients with T2D and diabetic kidney disease (DKD). Design: Systematic review. Setting: Randomized controlled trials (RCTs) conducted in any country. Patients: Adults with T2D and DKD receiving supplementation with any form of native vitamin D (eg, ergocalciferol, cholecalciferol, calcifediol). Measurements: Clinical outcomes and surrogate clinical and laboratory measures reported in each of the trials were included in this review. Methods: The following databases were searched from inception to January 31, 2023: Embase, MEDLINE, Cochrane CENTRAL, Web of Science, ProQuest Dissertations and Theses, and medRxiv. Only RCTs examining supplementation with a native vitamin D form with a control or placebo comparison group were included. We excluded studies reporting only vitamin D status or mineral metabolism parameters, without any other outcomes of clinical relevance or surrogate laboratory measures. Study quality was evaluated using the Cochrane risk-of-bias tool (RoB2). Results were synthesized in summary tables for each type of outcome with the P values from the original studies displayed. Results: Nine publications were included, corresponding to 5 separate RCTs (377 participants total). Mean age ranged from 40 to 63. All trials administered vitamin D3. Intervention groups experienced improvements in vitamin D status and a reduction in proteinuria in 4 of the 5 included RCTs. There was a decrease in low-density lipoprotein and total cholesterol in the 2 trials in which they were measured. Improvements in bone mass, flow-mediated dilation, and inflammation were also reported, but each was only measured in 1 RCT. Effects on glucose metabolism, high-density lipoprotein, triglycerides, blood pressure, oxidative stress, and kidney function were mixed. No serious adverse effects were reported. Limitations: Limitations include the small number of RCTs and lack of information on the use of drugs that affect measured outcomes (eg, proteinuria-lowering renin-angiotensin-aldosterone system inhibitors and lipid-lowering medication) in most studies. Our study is also limited by the absence of a prestudy protocol and registration. Conclusions: Native vitamin D is a safe treatment that improves vitamin D status in patients with DKD. Vitamin D may modify proteinuria and lipid metabolism in DKD, but further well-designed trials that include well-established treatments are necessary. Overall, there is limited evidence for beneficial pleiotropic effects of vitamin D in patients with DKD.

show abstract

Effect of vitamin D on urinary angiotensinogen level in early diabetic nephropathy

Cited by 7 publications

References 25 publications

A Retrospective Analysis of the Relationship Between 25-OH-Vitamin D and Diabetic Foot Ulcer

A Retrospective Analysis of the Relationship Between 25-OH-Vitamin D and Diabetic Foot Ulcer

The Effect of Vitamin D3 and Silver Nanoparticles on HaCaT Cell Viability

Are There Any Pleiotropic Benefits of Vitamin D in Patients With Diabetic Kidney Disease? A Systematic Review of Randomized Controlled Trials

Contact Info

Product

Resources

About